Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 20/20 | 0.73 |
| ▸ | CA1 | P00915 | 15/20 | 0.73 |
| ▸ | CA9 | Q16790 | 14/20 | 0.73 |
| ▸ | CA12 | O43570 | 13/20 | 0.73 |
| ▸ | CA14 | Q9ULX7 | 10/20 | 0.73 |
| ▸ | CA4 | P22748 | 5/20 | 0.70 |
| ▸ | CA6 | P23280 | 5/20 | 0.70 |
| ▸ | CA5A | P35218 | 5/20 | 0.70 |
| ▸ | CA7 | P43166 | 5/20 | 0.70 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfamide SCHEMBL5585371 | 0.97 | CA2 (0.70) | CA2CA1CA9CA12CA14 | |
| SCHEMBL10690610 | 0.91 | CA2 (0.89) | CA2CA1CA9CA12CA14 | |
| SCHEMBL27816697 | 0.89 | CA2 (0.75) | CA2CA1CA9CA12CA14 | |
| SCHEMBL27959272 | 0.87 | CA2 (0.59) | CA2CA1CA9CA12CA14 | |
| SCHEMBL202948 | 0.83 | CA2 (0.81) | CA2CA1CA9CA12CA14 | |
| Mafenide SCHEMBL41628 | 0.82 | CA2 (1.00) | CA2CA1CA9CA12CA14 | |
| SCHEMBL1804376 | 0.82 | CA2 (0.67) | CA2CA1CA9CA12CA14 | |
| Mafenide SCHEMBL9295695 | 0.82 | CA2 (1.00) | CA2CA1CA9CA12CA14 | |
| SCHEMBL14505689 | 0.80 | CA2 (0.64) | CA2CA1CA9CA12CA14 | |
| SCHEMBL13256756 | 0.80 | CA2 (0.64) | CA2CA1CA9CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 346 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-12605384-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-3746081-B1 | PDE1 INHIBITORS FOR USE TO TREAT CARDIAC FAILURE AND CARDIOTOXICITY | INTRA CELLULAR THERAPIES INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260049314-A1 | ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS | UNIVERSITY OF ROCHESTER (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4581143-A1 | ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS | University of Rochester (US) | 2025-07-09 | — | — | EP | disclosed |
| US-20250066790-A1 | ANTISENSE OLIGONUCLEOTIDES FOR MODIFYING PROTEIN EXPRESSION | UNIVERSITY OF ROCHESTER | 2025-02-27 | — | — | US | disclosed |
| US-20250018009-A1 | SERUM RESPONSE FACTOR REGENERATES SENESCENT CELLS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2025-01-16 | — | — | US | disclosed |
| US-20250019702-A1 | GATA4-TARGETED THERAPEUTICS FOR TREATMENT OF CARDIAC HYPERTROPHY | UNIVERSITY OF ROCHESTER | 2025-01-16 | — | — | US | disclosed |
| EP-3542160-B1 | INHIBITORS OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE FOR TREATING CARDIOVASCULAR AND PULMONARY CONDITIONS | ICHOR LLC (US) | 2025-01-01 | — | — | EP | disclosed |
| EP-4444881-A2 | GATA4-TARGETED THERAPEUTICS FOR TREATMENT OF CARDIAC HYPERTROPHY | University of Rochester (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | disclosed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | disclosed |
| US-6024976-A | TRANSDERMAL DRUG DELIVERY WITH PRESSURE SENSITIVE ADHESIVE COMPOSITION OF POLYVINYLPYRROLIDONE WITH DRUG IN MULTILAYER PATCH | NOVEN PHARMACEUTICALS, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| US-5719197-A | DRUG DELIVERY | NOVEN PHARMACEUTICALS, INC. (US) | 1998-02-17 | — | — | US | disclosed |
| US-5656286-A | BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE | NOVEN PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1996040084-A1 | COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040086-A2 | COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5446070-A | Flexible, finite, bioadhesive, therapeutical agent in solid form | NOVER PHARMACEUTICALS, INC. (US) | 1995-08-29 | — | — | US | disclosed |
| US-4855289-A | Combination of two active substances | WESTER PER O (SE) | 1989-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049314-A1 | ANTISENSE OLIGONUCLEOTIDE-BASED ANTI-FIBROTIC THERAPEUTICS | UPF1, HNRNPF, RNMT | CA2 4725/4885CA1 4883/4885CA9 4535/4885 |
| US-20250019702-A1 | GATA4-TARGETED THERAPEUTICS FOR TREATMENT OF CARDIAC HYPERTROPHY | UPF1, TNNI3, TNNT2 | CA2 3850/4885CA1 4765/4885CA9 4815/4885 |
| US-12605384-B2 | Uses | PDE2A, NPR1, PDE7A | CA2 997/4885CA1 3340/4885CA9 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.